KCM
TYRA icon

Kynam Capital Management’s Tyra Biosciences TYRA Stock Holding History

Kynam Capital Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,564,492
Closed -$41.1M – 44
2025
Q4 		$41.1M Sell
1,564,492
-765,506
-33% -$14.1M 2.63% 9
2025
Q3 		$32.6M Hold
2,329,998
– – 2.43% 14
2025
Q2 		$22.3M Sell
2,329,998
-76,069
-3% -$723K 2.4% 13
2025
Q1 		$22.4M Buy
2,406,067
+1,875,589
+354% +$24.3M 1.88% 15
2024
Q4 		$7.37M Buy
530,478
+62,531
+13% +$1.13M 0.44% 22
2024
Q3 		$11M Sell
467,947
-98,768
-17% -$2.07M 0.84% 20
2024
Q2 		$9.06M Buy
566,715
+51,525
+10% +$887K 0.7% 20
2024
Q1 		$8.45M Buy
515,190
+175,000
+51% +$2.87M 0.88% 19
2023
Q4 		$4.71M Buy
+340,190
New +$4.4M 0.52% 23

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
APMC
Alta Partners Management Company Jackson, Wyoming $151M AUM 296.21% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Kynam Capital Management's TYRA Position: Q1 2026 in Review

Kynam Capital Management sold out of Tyra Biosciences (TYRA) in Q1 2026, closing a stake of 1,564,492 shares — an estimated $41.1M sold.

Kynam Capital Management first reported a position in TYRA in Q4 2023 and held it in 9 quarters. The position peaked at $41.1M in Q4 2025. 164 funds tracked by Wall St. Rank hold TYRA as of Q1 2026.

  • Kynam Capital Management reported no remaining Tyra Biosciences position as of Q1 2026 after selling out during the quarter.
  • Kynam Capital Management sold 1,564,492 Tyra Biosciences shares in Q1 2026, an estimated $41.1M.
  • Kynam Capital Management first reported a position in Tyra Biosciences in Q4 2023 and held it in 9 quarters.
  • Kynam Capital Management's Tyra Biosciences position peaked at $41.1M in Q4 2025.
  • 164 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2026.

Based on Kynam Capital Management's 13F filing for Q1 2026, filed 15 May 2026.